Litigation Details for Onyx Therapeutics, Inc. v. CIPLA Limited (D. Del. 2016)
✉ Email this page to a colleague
Onyx Therapeutics, Inc. v. CIPLA Limited (D. Del. 2016)
| Docket | ⤷ Subscribe | Date Filed | 2016-10-24 |
| Court | District Court, D. Delaware | Date Terminated | 2023-02-21 |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory B. Williams |
| Jury Demand | None | Referred To | |
| Parties | DR. REDDY'S LABORATORIES LTD. | ||
| Patents | 7,232,818; 7,417,042; 7,491,704; 7,737,112; 8,129,346; 8,207,125; 8,207,126; 8,207,127; 8,207,297 | ||
| Attorneys | Barry P. Golob | ||
| Firms | Phillips, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Onyx Therapeutics, Inc. v. CIPLA Limited
The small molecule drug covered by the patents cited in this case is ⤷ Subscribe .
Biologic Drugs cited in Onyx Therapeutics, Inc. v. CIPLA Limited
The biologic drugs covered by the patents cited in this case are ⤷ Subscribe and ⤷ Subscribe .
Details for Onyx Therapeutics, Inc. v. CIPLA Limited (D. Del. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2016-10-24 | 1 | Complaint | 16. United States Patent No. 7,232,818 (the “’818 Patent”), entitled “Compounds For Enzyme Inhibition…Product prior to the expiration of U.S. Patent Nos. 7,417,042; 7,232,818; 7,491,704; 7,737,112; 8,129,346;… COUNT II: INFRINGEMENT OF U.S. PATENT NO. 7,232,818 53. Plaintiff hereby realleges… THE PATENTS-IN-SUIT 15. United States Patent No. 7,417,042 (the “’042 Patent”), entitled… This is a civil action for patent infringement under the patent laws of the United States, Title | External link to document |
| 2018-04-17 | 203 | Redacted Document | Relevant Onyx’s U.S. Patent No. 7,737,112 (“Onyx’s formulation patent”) contains claims directed…by claims of the Patents-in-Suit. In this litigation, Onyx is asserting five patents, which are directed…alternative formulations to the patented formulations or to “design around” the Patents-in-Suit (Topics 3-5 of …own patents on formulations of carfilzomib. These defendants are effectively arguing to the Patent Office…. (“Onyx”) in the above-referenced matter. This patent infringement action, arising under the Hatch-Waxman | External link to document |
| 2018-06-26 | 240 | Notice of Service | Opening Expert Report on Invalidity of U.S. Patent Nos. 7,417,042; 7,737,112; 8,207,125; 8,207,126 and 8,207,127… 2016 15 May 2020 1:16-cv-00988 830 Patent None District Court, D. Delaware | External link to document |
| 2018-08-09 | 247 | Notice of Service | Amiji, Ph.D., R.Ph on Invalidity of U.S. Patent Nos. 7,417,042; 7,737,112; 8,207,125; 8,207,126 and 8,207,127… 2016 15 May 2020 1:16-cv-00988 830 Patent None District Court, D. Delaware | External link to document |
| 2018-10-10 | 273 | Notice of Service | Amiji, Ph.D., R.Ph on Invalidity of U.S. Patent Nos. 7,417,042; 7,737,112; and 8,207,125 filed by InnoPharma… 21 February 2023 1:16-cv-00988 830 Patent None District Court, D. Delaware | External link to document |
| 2016-10-24 | 3 | ANDA Form | - April, 14, 2025 7,232,818 - April, 14, 2025 8,207,126 - April, 14, 2025 7,491,704 - April, 14, 2025 … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …Received Notice: 09/12/2016. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 1/20/…USA, INC. ‘me eee SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG APPLICATION…Notice: September 12, 2016 Date of Expiration of Patent: See Below** Thirty Month Stay Deadline: January | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
